RE: New Spotlight is out1 Oct 2025 20:16
'In-licensing occurs when pharmaceutical companies acquire rights to compounds, technologies, or products from external sources. This strategy allows companies to add promising assets to their development pipeline without performing the initial research themselves. In 2025, this approach has become increasingly common as R&D costs continue to rise and success rates for internal drug discovery remain challenging.
The core mechanics of in-licensing typically involve upfront payments, milestone payments tied to development stages, and royalties on sales if the product reaches the market. The financial structure varies widely based on the development stage of the asset, with early-stage compounds commanding lower upfront costs but higher risk profiles. Late-stage assets with positive clinical data typically require larger initial investments but offer reduced developmental risk and faster time to market.
For pharmaceutical executives, in-licensing serves as a strategic tool to address specific portfolio gaps. When a company identifies therapeutic areas where their internal pipeline lacks strength, in-licensing provides a faster route to market presence than starting research from scratch. This approach proves particularly valuable when trying to enter specialized fields where the company lacks historical expertise or when facing patent cliffs for existing blockbuster drugs.
Recent In-Licensing Success Stories
Novartis’s 2024 in-licensing deal with BioTech Innovations stands as a prime example of strategic portfolio expansion. By acquiring rights to a Phase II small molecule targeting treatment-resistant depression, Novartis expanded its neuroscience portfolio in an area experiencing growing demand. The deal structure included $210 million upfront with potential milestone payments reaching $1.8 billion, reflecting the compound’s promising Phase I results and market potential.
Similarly, AstraZeneca strengthened its oncology pipeline through in-licensing a novel antibody-drug conjugate from ImmunoCore Therapeutics in early 2025. The compound demonstrated remarkable efficacy against certain triple-negative breast cancers in early trials, filling a critical gap in AstraZeneca’s treatment offerings. This strategic move allowed AstraZeneca to rapidly position itself in a competitive therapeutic area without the 7-10 years typically required for internal development'
Sign In
Follow the stocks
